IL125034A0 - Vitronectin receptor antagonists - Google Patents
Vitronectin receptor antagonistsInfo
- Publication number
- IL125034A0 IL125034A0 IL12503496A IL12503496A IL125034A0 IL 125034 A0 IL125034 A0 IL 125034A0 IL 12503496 A IL12503496 A IL 12503496A IL 12503496 A IL12503496 A IL 12503496A IL 125034 A0 IL125034 A0 IL 125034A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- vitronectin receptor
- vitronectin
- antagonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US953295P | 1995-12-29 | 1995-12-29 | |
PCT/US1996/020744 WO1997024122A1 (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL125034A0 true IL125034A0 (en) | 1999-01-26 |
Family
ID=21738237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12503496A IL125034A0 (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0895475A4 (en) |
JP (1) | JP2000502708A (en) |
KR (1) | KR19990076876A (en) |
CN (1) | CN1209060A (en) |
AU (1) | AU1353897A (en) |
BR (1) | BR9612378A (en) |
CA (1) | CA2241724A1 (en) |
CZ (1) | CZ203798A3 (en) |
HU (1) | HUP9901116A2 (en) |
IL (1) | IL125034A0 (en) |
MX (1) | MX9805253A (en) |
NO (1) | NO983002L (en) |
PL (1) | PL327919A1 (en) |
TR (1) | TR199801255T2 (en) |
WO (1) | WO1997024122A1 (en) |
ZA (1) | ZA9610855B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0777657A1 (en) * | 1994-08-22 | 1997-06-11 | Smithkline Beecham Corporation | Bicyclic compounds |
JP2000516197A (en) * | 1996-01-16 | 2000-12-05 | メルク エンド カンパニー インコーポレーテッド | Integrin receptor antagonist |
ATE227268T1 (en) * | 1996-04-10 | 2002-11-15 | Merck & Co Inc | ALPHA V BETA 3 ANTAGONISTS |
US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
DE19653645A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
DE19653647A1 (en) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
US6239138B1 (en) * | 1997-07-25 | 2001-05-29 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
JP2002508323A (en) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | Integrin receptor antagonist |
ID26223A (en) * | 1998-03-10 | 2000-12-07 | Smithkline Beecham Corp | VITRONEKTIN RECEPTOR ANTAGONISTS |
UA66842C2 (en) * | 1998-04-01 | 2004-06-15 | Янссен Фармацевтика Н.В. | Pyridine derivatives as inhibitors of pde iv |
GB9812088D0 (en) * | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
SE9803518D0 (en) * | 1998-10-15 | 1998-10-15 | Astra Pharma Prod | Novel compounds |
JP2002536370A (en) | 1999-02-03 | 2002-10-29 | メルク エンド カムパニー インコーポレーテッド | Benzoazepine derivatives as α-V integrin receptor antagonists |
US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
CA2378860A1 (en) | 1999-07-21 | 2001-02-01 | American Home Products Corporation | Bicyclic antagonists selective for the .alpha.v.beta.3 integrin |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
DE10028575A1 (en) | 2000-06-14 | 2002-03-14 | Basf Ag | integrin |
FR2800067B1 (en) | 1999-10-21 | 2004-12-17 | Rhodia Chimie Sa | INTERMEDIATES FOR THE MANUFACTURE OF A BENZOFURANE OR NITROGEN BENZOTHIOPHENE DERIVATIVE IN POSITION 5 AND THEIR USES |
FR2820743B1 (en) | 2001-02-09 | 2005-02-25 | Pf Medicament | SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES |
CA2444821C (en) | 2001-04-24 | 2012-07-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using anti-angiogenic agents and tnfa |
EP1678168B1 (en) * | 2003-10-24 | 2012-07-11 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
WO2006041046A1 (en) * | 2004-10-13 | 2006-04-20 | Sankyo Company, Limited | Pyridine derivative |
MX2007013198A (en) | 2005-04-20 | 2008-03-24 | Johnson & Johnson | Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls. |
WO2007084670A2 (en) | 2006-01-18 | 2007-07-26 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
AR060901A1 (en) * | 2006-05-12 | 2008-07-23 | Jerini Ag | HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE |
AU2008207095B2 (en) | 2007-01-18 | 2013-08-29 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer |
US9345739B2 (en) | 2007-11-08 | 2016-05-24 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
MX2011012345A (en) | 2009-05-22 | 2012-01-31 | Exelixis Inc | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases. |
US20120130146A1 (en) | 2009-05-25 | 2012-05-24 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
RU2573637C2 (en) * | 2009-12-17 | 2016-01-27 | Басф Се | Method for synthesis of higher ethanolamines |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
KR20160147007A (en) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | Carbonitrile derivatives as selective androgen receptor modulators |
US10975056B2 (en) | 2016-06-13 | 2021-04-13 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of DNMT1 |
EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
TW201835078A (en) | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | Inhibitors of [alpha]v[beta]6 integrin |
SG11202101913PA (en) | 2018-08-29 | 2021-03-30 | Morphic Therapeutic Inc | INHIBITING aV ß6 INTEGRIN |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
JP3497164B2 (en) * | 1991-06-28 | 2004-02-16 | スミスクライン・ビーチャム・コーポレイション | Bicyclic fibrinogen antagonist |
CA2152631A1 (en) * | 1992-12-21 | 1994-07-07 | William Edward Bondinell | Bicyclic fibrinogen antagonists |
JPH10504807A (en) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | Vitronectin receptor antagonist |
ZA9610853B (en) * | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
PL327626A1 (en) * | 1995-12-29 | 1998-12-21 | Smithkline Beecham Corp | Antagonists of vitronectin receptor |
-
1996
- 1996-12-20 IL IL12503496A patent/IL125034A0/en unknown
- 1996-12-20 WO PCT/US1996/020744 patent/WO1997024122A1/en not_active Application Discontinuation
- 1996-12-20 AU AU13538/97A patent/AU1353897A/en not_active Abandoned
- 1996-12-20 JP JP9524556A patent/JP2000502708A/en active Pending
- 1996-12-20 TR TR1998/01255T patent/TR199801255T2/en unknown
- 1996-12-20 KR KR1019980705003A patent/KR19990076876A/en not_active Application Discontinuation
- 1996-12-20 HU HU9901116A patent/HUP9901116A2/en unknown
- 1996-12-20 CA CA002241724A patent/CA2241724A1/en not_active Abandoned
- 1996-12-20 CN CN96180099A patent/CN1209060A/en active Pending
- 1996-12-20 EP EP96945085A patent/EP0895475A4/en not_active Withdrawn
- 1996-12-20 BR BR9612378A patent/BR9612378A/en unknown
- 1996-12-20 PL PL96327919A patent/PL327919A1/en unknown
- 1996-12-20 CZ CZ982037A patent/CZ203798A3/en unknown
- 1996-12-23 ZA ZA9610855A patent/ZA9610855B/en unknown
-
1998
- 1998-06-26 MX MX9805253A patent/MX9805253A/en unknown
- 1998-06-26 NO NO983002A patent/NO983002L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TR199801255T2 (en) | 1998-10-21 |
AU1353897A (en) | 1997-07-28 |
JP2000502708A (en) | 2000-03-07 |
NO983002D0 (en) | 1998-06-26 |
NO983002L (en) | 1998-08-26 |
CZ203798A3 (en) | 1998-12-16 |
WO1997024122A1 (en) | 1997-07-10 |
ZA9610855B (en) | 1997-11-24 |
CA2241724A1 (en) | 1997-07-10 |
HUP9901116A2 (en) | 2000-03-28 |
CN1209060A (en) | 1999-02-24 |
EP0895475A1 (en) | 1999-02-10 |
MX9805253A (en) | 1998-10-31 |
PL327919A1 (en) | 1999-01-04 |
EP0895475A4 (en) | 2000-08-23 |
KR19990076876A (en) | 1999-10-25 |
BR9612378A (en) | 1999-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL125030A0 (en) | Vitronectin receptor antagonists | |
IL125033A0 (en) | Vitronectin receptor antagonists | |
IL125034A0 (en) | Vitronectin receptor antagonists | |
EP0767792A4 (en) | Vitronectin receptor antagonists | |
ZA955391B (en) | Vitronectin receptor antagonists | |
CY2576B1 (en) | Vitronectin receptor antagonists | |
HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
IL125717A0 (en) | Il-8 receptor antagonists | |
EP1000031A4 (en) | Vitronectin receptor antagonist | |
ZA9896B (en) | Vitronectin receptor antagonists | |
IL135189A0 (en) | Vitronectin receptor antagonist | |
IL135028A0 (en) | Vitronectin receptor antagonists | |
IL135188A0 (en) | Vitronectin receptor antagonist | |
HUP9902817A3 (en) | Endothelin receptor antagonists | |
HU9602054D0 (en) | Endothelin receptor antagonists | |
EP0854721A4 (en) | Endothelin receptor antagonists | |
EP0841926A4 (en) | Endothelin receptor antagonists | |
EP0841916A4 (en) | Endothelin receptor antagonists | |
EP0868180A4 (en) | Endothelin receptor antagonists | |
SI0957917T1 (en) | Vitronectin receptor antagonists | |
ZA988562B (en) | Vitronectin receptor antagonists | |
ZA966592B (en) | Endothelin receptor antagonists | |
IL141121A0 (en) | Il-8 receptor antagonists |